Arif Albulushi
Advanced Heart Failure and Transplant Cardiology · Bellevue, NENPI 1467906487
Payments from drug & device makers
Across 157 payments — averaging $322.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kiniksa Pharmaceuticals, Ltd.$25K
- Medtronic$10K
- Merck$9K
- Abbott$5K
- Lilly USA, LLC$520
- Novartis$449
- plus $1K from 9 others
What the payments were for
- Speaking & faculty fees$28,84057%
- Grants$8,75017%
- Travel & lodging$7,55115%
- Food & beverage$5,13610%
- Education$4051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | 33 | $25,398 |
| Medtronic(2 entities) | 9 | $9,635 |
| Merck | 9 | $8,841 |
| Abbott | 67 | $4,747 |
| Lilly USA, LLC | 1 | $520 |
| Novartis | 16 | $449 |
| Actelion Pharmaceuticals US, Inc. | 4 | $351 |
| Itamar Medical Inc | 1 | $203 |
| Bayer | 3 | $157 |
| Abiomed | 2 | $151 |
| Pfizer | 7 | $100 |
| Boehringer Ingelheim | 2 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $49 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARCALYST$24,721
- VERQUVO$17,408
- HeartWare HVAD$8,750
- HeartMate PHP$1,253
- CARDIOMEMS$1,011
- HeartMate 3 Left Ventricular Dev$560
- JARDIANCE$520
- CardioMEMS HF System$449
- ENTRESTO$222
- UPTRAVI$217
- WatchPATONE$203
- HeartMate 3 Left Ventricular Assist Device$174
- Adempas$125
- LEQVIO$116
- OPSUMIT$101
How this compares
Too few advanced heart failure and transplant cardiology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 100 | $101,431 |
| JardianceEmpagliflozin | 85 | $88,394 |
| EliquisApixaban | 23 | $22,486 |
| FarxigaDapagliflozin Propanediol | 17 | $18,638 |
| Metoprolol Succinate | 94 | $1,524 |
| Torsemide | 29 | $1,434 |
| Spironolactone | 96 | $711 |
| Potassium Chloride | 11 | $618 |
| Losartan Potassium | 45 | $364 |
| Ezetimibe | 24 | $335 |
| Fenofibrate | 14 | $262 |
| Rosuvastatin Calcium | 27 | $200 |
| Atorvastatin Calcium | 20 | $158 |
| ClopidogrelClopidogrel Bisulfate | 19 | $113 |
| Furosemide | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $449 | $101,431100 claims |
| Boehringer IngelheimJardiance | $50 | $88,39485 claims |
| PfizerEliquis | $100 | $22,48623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Bellevue
- Douglas StollerOmaha$645K
- Mathue BakerLincoln$639K
- Scott LundgrenOmaha$230K
- Selma MohammedOmaha$139K
- Brian LowesOmaha$24K
- Jason ColeOmaha$155
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.